# Revvity, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Revvity, Inc). ## Overview Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows. Its business spans translational multi-omics, biomarker discovery, imaging, informatics, and diagnostic testing, with products and services sold globally from its headquarters in Waltham, Massachusetts. ## Products & services • Life Sciences Solutions instruments and reagents • Software for scientific data and workflow management • Immunodiagnostics assays and testing systems • Reproductive Health screening and diagnostic products • Imaging and detection technologies • Scientific services and workflow support - **Life Sciences Solutions** (51%) — Instruments, reagents, and consumables used in research and discovery workflows. - **Software** (10%) — Informatics and workflow software used to manage scientific and lab data. - **Immunodiagnostics** (24%) — Diagnostic assays and systems used in clinical and laboratory testing. - **Reproductive Health** (15%) — Screening and diagnostic products used in prenatal and reproductive testing. - Life Sciences Solutions instruments and reagents - Software for scientific data and workflow management - Immunodiagnostics assays and testing systems - Reproductive Health screening and diagnostic products - Imaging and detection technologies - Scientific services and workflow support ## Customers Revvity sells to research institutions, biopharma and biotech companies, clinical laboratories, and healthcare providers that need specialized tools for discovery, screening, and diagnosis. It also serves public and private organizations involved in reproductive health and disease testing, where workflow reliability, regulatory compliance, and analytical performance matter. The company markets through specialized sales forces and distributors, so customer relationships are typically technical and application-driven rather than transactional. - **Academic and government research institutions** (primary) — Buy instruments, reagents, and software for discovery, biomarker, and translational research. - **Biopharma and biotech companies** (primary) — Buy workflow technologies for screening, assay development, and development-stage research. - **Clinical laboratories** (primary) — Buy immunodiagnostics systems and assays for routine and specialized testing. - **Reproductive health providers and labs** (secondary) — Buy prenatal screening and reproductive diagnostic products used in clinical workflows. - **Healthcare and diagnostic service networks** (secondary) — Buy integrated testing and informatics solutions to support lab operations and reporting. - Academic and government research labs buying discovery tools - Biopharma and biotech customers buying workflow technologies - Clinical laboratories buying diagnostic assays and systems - Healthcare providers using reproductive health screening products - Customers value analytical performance, reliability, and compliance ## Geography Revvity markets its products and services in more than 160 countries and operates sales and service teams in about 40 countries. The company is headquartered in the United States, but its business is internationally diversified, with sales outside the U.S. representing the majority of revenue and with manufacturing, employees, and suppliers also located abroad. - **United States** (45%) — Estimated from the company’s disclosure that international sales are the majority of revenue. - **International** (55%) — Estimated remainder of revenue outside the United States. - Headquartered in Waltham, Massachusetts, United States - Products and services sold in more than 160 countries - Sales and service presence in about 40 countries - Majority of revenue comes from outside the United States - International manufacturing and supplier footprint increases FX exposure ## Strategy Revvity’s strategy centers on expanding in high-growth health science markets by broadening its product and service offerings and investing in research and development. It also emphasizes innovation, acquisitions of technology, and global commercial reach to strengthen its position across discovery, screening, and diagnostics workflows. - **Broaden the health science workflow portfolio** (medium-term) — A wider portfolio increases cross-sell opportunities and makes the company more embedded in customer workflows. - **Invest in innovation and new product development** (short-term) — The market changes quickly, so timely product launches are needed to defend share and support growth. - **Expand global commercial reach** (medium-term) — A broad international footprint supports access to more customers and reduces dependence on any one market. - Expand offerings across discovery, screening, and diagnostics workflows - Invest in R&D to launch new technologies and applications - Use acquisitions to add capabilities and broaden the portfolio - Strengthen global product and service coverage - Improve customer experience and product quality ## Risks Revvity faces demand, regulatory, and technology risks because its products are sold into healthcare and research markets that depend on funding, approvals, and rapid innovation. Its international footprint also exposes it to foreign exchange, trade, and geopolitical effects, while goodwill and acquisition-related assets require ongoing impairment testing. - **Market demand tied to funding and economic conditions** [high] — Customers in research and healthcare may delay purchases when budgets or approvals are uncertain. - **Regulatory compliance risk** [high] — Some products are subject to FDA and foreign agency oversight, and non-compliance can restrict sales. - **Technology obsolescence and product launch timing** [high] — The industry changes quickly, so delayed or weak new products can lead to share loss. - **Foreign exchange and international operating risk** [medium] — Most revenue is generated outside the U.S., and many suppliers and employees are abroad. - **Goodwill impairment risk** [medium] — Acquisition-related goodwill depends on future cash flow assumptions and market valuations. - Demand can weaken if research or healthcare funding slows - Healthcare and diagnostic products face changing regulation - Rapid innovation creates obsolescence and competitive risk - International sales expose the company to FX and trade effects - Goodwill and intangibles can be impaired if assumptions weaken ## Accounting Revvity’s reported results are sensitive to goodwill and intangible asset valuation, because acquisitions create balances that must be tested for impairment using cash flow and discount-rate assumptions. Revenue and margin comparisons are also affected by foreign exchange, tariffs, product mix, and timing of collections, while quarterly results can vary with customer ordering patterns and geographic mix. - **Goodwill impairment testing** — Could create non-cash impairment charges if expected cash flows weaken - **Acquisition-related intangibles** — Affects operating income and balance sheet valuation - **Foreign currency translation** — Can move reported growth and margins without changing underlying demand - **Working capital and cash flow timing** — Affects quarterly and annual cash conversion - Goodwill impairment depends on cash flow and discount-rate assumptions - Acquisition accounting affects intangibles and future amortization - Foreign exchange can change reported revenue and margins - Tariffs and product mix affect gross margin comparability - Working-capital timing can shift cash flow between periods --- *Last updated: 2026-09-24T11:43:51.589452+00:00*